MedTrace Logo

Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals

NCT01381029 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2023-05-19

No results posted yet for this study

Summary

Investigators in the Division of Infectious Diseases are carrying out a study to determine if human immunodeficiency virus (HIV)-seropositive patients receiving the Seasonal Influenza vaccination develop an adequate antibody response. The study group will consist of individuals seen in the Infectious Diseases Clinic who are HIV-seropositive and receive the Seasonal Influenza vaccine.

Conditions

  • Influenza, Human
  • Human Immunodeficiency Virus I Infection

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Principal Investigators

  • Marc Siegel, MD · George Washington University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381029 on ClinicalTrials.gov